ClinicalTrials.gg
RecruitingNCT07277582Wave IIUpdated Sep 21, 2026

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

A Phase 2/3 interventional study of baseline lead-in and THRV-1268 in Long QT Syndrome (LQTS) 2, sponsored by Thryv Therapeutics, Inc.. Recruiting at 9 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Thryv Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.

Planned enrollment
5th of 28
84 · median 44
Started
2026
the only one that year
Phase 2/3
Only one
of the 44
Registered
44th of 44
by date
Lead sponsor
3 of 44
Thryv Therapeutics, Inc.

Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 5th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2/3, and was the 44th registered.

Long QT Syndrome

101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.

Browse Long QT Syndrome studies →

Open to participants now

7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Long QT Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2) and Long QT Syndrome Type 3 (LQTS 3). The study will also learn about the safety and tolerability of THRV-1268 at different doses.

The main questions this study aims to answer are:

Does THRV-1268 reduce the QTc interval (a measure of the heart's electrical recovery time)?

What side effects or medical problems occur when participants take THRV-1268?

Which dose of THRV-1268 works best and is safest?

Participants will:

Complete a 3-week observation period with ECG and Holter monitoring to establish baseline QTc measurements Take THRV-1268 twice daily at two dose levels for 6 weeks (Part A) or be randomly assigned to a dose group for 6 weeks (Part B - cohort 1)

Have clinic visits and tests to monitor safety and changes in their heart rhythm

May continue taking THRV-1268 for up to 1 year for ongoing safety and efficacy evaluation

Researchers will compare changes in QTc over time and evaluate side effects to determine whether THRV-1268 can help reduce the risk of abnormal heart rhythms and sudden cardiac events in people with LQTS 2 and LQTS 3.

03

Conditions studied

  • Long QT Syndrome (LQTS) 2

Browse trials for

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants over 15 years of age at Screening (at least the first 3 participants enrolled in Part A must be 18 years of age or older).
  • Part A and Part B Cohort 1 LQTS 2 genotype: Demonstration of KCNH2 mutation by clinical laboratory test result that is autosomal dominant (heterozygous) and considered to be pathologic or likely pathologic can be included after approval from the sponsor medical monitor or qualified delegate.
  • Part B, Cohort 2 LQTS 3 genotype: Demonstration of SCN5A mutation by clinical laboratory test result that is autosomal dominant (heterozygous) and considered to be pathologic or likely pathologic for LQTS (and not Brugada syndrome) can be included after approval from the sponsor medical monitor or qualified delegate.
  • interval >480 ms and ≤600 ms based on Screening .
  • Body weight of at least 45 kg with between 18.0 and 40.0 kg/m2, inclusively at Screening.
  • Male and female participants of must agree to use highly effective throughout the duration of the study.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Participants age 15 to \<18 years capable of providing signed assent.

Exclusion criteria

Exclusion Criteria:

  • Within 1 month prior to Screening, Participant has a history of an aborted cardiac arrest, ICD implantation, or syncopal episode due to a ventricular arrhythmia.
  • History of structural or functional cardiovascular disease, myocardial infarction or stroke or (TIA), persistent atrial fibrillation or atrial flutter, heart failure, bundle branch block, angina pectoris, or hemodynamically significant ventricular tachycardia not due to TdP. (Individuals with history of paroxysmal atrial fibrillation are allowed if in sinus rhythm at time of screening and enrollment.)
  • Active or known liver disease.
  • Active or past oncologic disease, except for non-melanoma skin cancer.
  • Advanced pulmonary disease that requires more than a inhaler.
  • Pulmonary artery hypertension.
  • Is pregnant, lactating, or breastfeeding, or planning to become pregnant.
  • Has a positive result for the urine pregnancy test at the Screening Visit or the serum pregnancy test at the Day -7 Visit.
  • abnormal findings on the physical examination or medical history during Screening or Day -21 as deemed by the investigator.
  • Has experienced an acute illness that has resolved in less than 14 days before the first study drug dose or has had a major illness or hospitalization within 1 month before the first study drug dose.
  • Has a recent history of alcohol or substance abuse that would pose a risk for the participant's safety and compliance with the study protocol, in the opinion of the investigator.
  • Has a pacemaker or ICD that is actively used for ventricular pacing.
  • Is currently taking or anticipates the use of any restricted drugs
  • Is known at the time of screening to be considering or scheduled to undergo any elective surgical procedure during the study.
  • Current participation or recent within 1 month of participating in another interventional clinical study.
  • Screening Visit diastolic blood pressure >95 mm Hg, systolic blood pressure \<90 or >150 mm Hg.
  • At Screening, if the 12-lead triplicate demonstrates any of the following: PR >280 ms; QRS >120 ms, or >600 ms or ≤480 ms; bundle branch block or significant ST-T wave abnormalities or flat T waves that could interfere with QT analysis. HR \<50 bpm, unless receiving a beta-blocker in which case \<40 bpm, or HR >100 bpm at rest.
  • Atrial pacing rate set to >80 bpm in those participants with atrial pacing.
  • Abnormal renal function with an of \<70 mL/min/1.73 m2 (with eGFR calculated by the CKD-EPI formula at Screening). One retest of the exclusionary eGFR value is allowed at the discretion of the investigator.
  • Has abnormal liver function tests:

    • , AST, GGT, ALP > 1.5 the .
    • Total >ULN.
    • >1.2 ULN (requires measurement of prothrombin time (PT)).
  • Has clinically significant abnormality in serum chemistry values at Screening for , potassium, magnesium, or calcium levels as determined by the investigator. A single repeat test and/or correction of abnormal values (e.g., electrolyte repletion) is permitted at the investigator's discretion prior to enrollment.
  • Any participant, who, for any reason, is deemed by the investigator to be inappropriate for this study or has any condition which would confound or interfere with the evaluation of the safety, tolerability, or efficacy of the medicinal product (IMP) or prevent compliance with the study protocol.
  • Consumes on average more than 21 standard alcoholic drinks per week in men and 14 standard drinks per week in women over the last 2 years.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    THRV-1268

    3 weeks lead-in baseline followed by 50 mg BID for 6 weeks with scheduled up-titration to 100 mg BID for another 6 weeks (12 weeks total treatment)

    Other: baseline lead-in · Drug: THRV-1268

Interventions

  • Otherbaseline lead-in

    Participants will undergo a 3 weeks run-in baseline

  • THRV-1268 50 mg bid (total daily 100 mg) for 6 weeks

  • THRV-1268 100 mg bid (total daily 200 mg) for 6 weeks

06

What researchers measure

Primary outcomes

  1. Part A: To evaluate the effect of oral THRV-1268 on QTcF interval by AUC method in participants with LQTS 2

    ΔAUC0-6 hours QTcF values on Day 42 (THRV-1268 50 mg BID) and Day 84 (THRV-1268 100 mg BID) compared to the the baseline (mean of Day -7 and Day -1).

    Time frame: Day 42 and Day 84

  2. Part A: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])

    To assess the safety and tolerability of two oral dose levels of THRV-1268 in participants with LQTS2 by measuring the incidence of treatment-emergent adverse events throughout the study.

    Time frame: up to 52 weeks

Secondary outcomes

  1. Part A: To evaluate the effects of oral THRV-1268 on QTcF interval by various methods in participants with LQTS 2

    QTcF values at each timepoint on Days 42 and 84 will be compared to the time-matched QTcF values on Baseline (mean of Day -7 and Day -1).

    Time frame: from 0 to 12 hours on Day 42 and 84

  2. Part A: To evaluate the effect of oral THRV-1268 on QTcF interval by AUC method in participants with LQTS 2

    ΔAUC0-12/12 QTcF values on Day 42 (THRV-1268 50 mg BID) and Day 84 (THRV-1268 100 mg BID) compared to the the baseline (mean of Day -7 and Day -1).

    Time frame: Day 42 and Day 84

  3. Part A: To evaluate the effect of oral THRV-1268 on QTcF interval by AUC method in participants with LQTS 2

    ΔAUC0-6 hours QTcF values on Day 42 (THRV-1268 50 mg BID) and Day 84 (THRV-1268 100 mg BID) compared to the the baseline (mean of Day -7 and Day -1) in patients with mean baseline AUC(0-6)/6 QTcF \>500 ms.

    Time frame: Day 42 and Day 84

  4. Part A: To evaluate the maximal shortening in QTcF from pre-dose to post-dose

    Measure the maximum delta between pre-dose QTcF (mean baseline values at Day-7 and Day-1) and lowest QTcF values reported on Day 42 and Day 84.

    Time frame: Day 42 and Day 84

07

Study locations

7 of 9 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 11, 2025
StartActual
Mar 7, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07277582
Lead sponsor
Thryv Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Mar 7, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Study Director
Contact
waveiistudyteam@thryvtrx.com
1-855-958-WAVE (9283)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THRV-1268

Start the discussion